Effectiveness and Safety of Ayurvedic Medicines in Type 2 Diabetes Mellitus Management: A Systematic Review and Meta-Analysis.
Effectiveness and Safety of Ayurvedic Medicines in Type 2 Diabetes Mellitus Management: A Systematic Review and Meta-Analysis.
复制标题
DOI：
10.3389/fphar.2022.821810
复制
发表时间：
2022
影响因子：
5.6
通讯作者：
Leonardi-Bee, Jo
中科院分区：
文献类型：
--
作者：
Chattopadhyay, Kaushik;Wang, Haiquan;Kaur, Jaspreet;Nalbant, Gamze;Almaqhawi, Abdullah;Kundakci, Burak;Panniyammakal, Jeemon;Heinrich, Michael;Lewis, Sarah Anne;Greenfield, Sheila Margaret;Tandon, Nikhil;Biswas, Tuhin Kanti;Kinra, Sanjay;Leonardi-Bee, Jo
简介：许多阿育吠陀药物具有治疗 2 型糖尿病 (T2DM) 的潜力，之前的系统评价已证明特定阿育吠陀药物的有效性和安全性。然而，许多评论需要更新，而且没有一篇评论提供了所有被评估用于治疗 T2DM 的阿育吠陀药物的全面总结。 目的：本系统评价的目的是评估和综合阿育吠陀药物治疗 T2DM 有效性和安全性的证据。 纳入标准：已发表和未发表的随机对照试验，评估阿育吠陀药物治疗成人 T2DM 的有效性和安全性。 方法：遵循 JBI 系统评价方法。对从开始到 2021 年 1 月 16 日期间的来源（包括 18 个电子数据库）进行了全面检索。没有应用语言限制。在适当的情况下，使用叙述合成和随机效应荟萃分析进行数据合成。汇总结果报告为具有 95% 置信区间 (CI) 的平均差 (MD)。 结果：在检索中确定的 32,519 条记录中，系统评价中纳入了 219 篇文章，代表 98 种阿育吠陀药物的 199 项随机对照试验（21,191 名受试者）。总体而言，在所审查的研究中，方法学没有得到充分报告，导致方法学质量评分较差。使用 Aegle marmelos (L.) Corrêa（MD -1.6%；95% CI -3 至 -0.3）、Boswellia serrata Roxb 降低糖化血红蛋白 (HbA1c)。 (-0.5；-0.7 至 -0.4)、绞股蓝 (-1；-1.5 至 -0.6)、苦瓜 (-0.3；-0.4 至 -0.1)、黑种草 (-0.4；-0.6 至 -0.1)、车前子。 （-0.9；-1.4 至 -0.3），Tinospora cordifolia (Wild.) Hook.f。与对照相比，Thomson（-0.5；-0.6至-0.5）、Trigonella foenum-graecum L.（-0.6；-0.9至-0.4）和Urtica dioica L.（-1.3；-2.4至-0.2）。同样，一系列阿育吠陀药物的空腹血糖 (FBG) 降低了 4–56 mg/dl。很少有研究评估与健康相关的生活质量（HRQoL）。许多研究都没有报告不良事件，即使报告了，这些不良事件也大多是无或轻微的，并且主要与胃肠道有关。 结论：目前的证据表明一系列阿育吠陀药物在改善 T2DM 患者的血糖控制方面具有益处。鉴于现有证据的局限性，为了加强证据基础，应进行和报告高质量的随机对照试验。
Introduction: Many Ayurvedic medicines have the potential for managing type 2 diabetes mellitus (T2DM), with previous systematic reviews demonstrating effectiveness and safety for specific Ayurvedic medicines. However, many of the reviews need updating and none provide a comprehensive summary of all the Ayurvedic medicines evaluated for managing T2DM. Objective: The objective of this systematic review was to evaluate and synthesize evidence on the effectiveness and safety of Ayurvedic medicines for managing T2DM. Inclusion criteria: Published and unpublished RCTs assessing the effectiveness and safety of Ayurvedic medicines for managing T2DM in adults. Methods: The JBI systematic review methodology was followed. A comprehensive search of sources (including 18 electronic databases) from inception to 16 January 2021 was made. No language restrictions were applied. Data synthesis was conducted using narrative synthesis and random effects meta-analyses, where appropriate. Pooled results are reported as mean differences (MD) with 95% confidence intervals (CI). Results: Out of 32,519 records identified from the searches, 219 articles were included in the systematic review representing 199 RCTs (21,191 participants) of 98 Ayurvedic medicines. Overall, in the studies reviewed the methodology was not adequately reported, resulting in poorer methodological quality scoring. Glycated hemoglobin (HbA1c) was reduced using Aegle marmelos (L.) Corrêa (MD -1.6%; 95% CI −3 to −0.3), Boswellia serrata Roxb. (−0.5; −0.7 to −0.4), Gynostemma pentaphyllum (Thunb.) Makino (−1; −1.5 to −0.6), Momordica charantia L. (−0.3; −0.4 to −0.1), Nigella sativa L. (−0.4; −0.6 to −0.1), Plantago ovata Forssk. (−0.9; −1.4 to −0.3), Tinospora cordifolia (Willd.) Hook.f. and Thomson (−0.5; −0.6 to −0.5), Trigonella foenum-graecum L. (−0.6; −0.9 to −0.4), and Urtica dioica L. (−1.3; −2.4 to −0.2) compared to control. Similarly, fasting blood glucose (FBG) was reduced by 4–56 mg/dl for a range of Ayurvedic medicines. Very few studies assessed health-related quality of life (HRQoL). Adverse events were not reported in many studies, and if reported, these were mostly none to mild and predominately related to the gastrointestinal tract. Conclusion: The current evidence suggests the benefit of a range of Ayurvedic medicines in improving glycemic control in T2DM patients. Given the limitations of the available evidence and to strengthen the evidence base, high-quality RCTs should be conducted and reported.
登录
查看更多内容
影响因子：
5.4
作者：
Abutair, Ayman S.;Naser, Ihab A.;Hamed, Amin T.
通讯作者：
Hamed, Amin T.
DOI：
10.1900/rds.2014.11.258
发表时间：
2014-09-01
期刊：
The review of diabetic studies : RDS
影响因子：
--
作者：
Azimi, Paria;Ghiasvand, Reza;Abbasi, Behnoud
通讯作者：
Abbasi, Behnoud
DOI：
10.3109/09637486.2014.880671
发表时间：
2014-06-01
影响因子：
3.9
作者：
Arablou, Tahereh;Aryaeian, Naheed;Djalali, Mahmoud
通讯作者：
Djalali, Mahmoud
影响因子：
3.6
作者：
Awasthi, Harshika;Nath, Rajendra;Sawlani, Kamal Kumar
通讯作者：
Sawlani, Kamal Kumar
影响因子：
7.2
作者：
Adibian, Mahsa;Hodaei, Homa;Hedayati, Mehdi
通讯作者：
Hedayati, Mehdi